Biotechnology

Wednesday Oct 21, 2026 - 2:44 pm

InvestorNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Aims for Greater Precision in Cancer Therapy

VERAXA Biotech (NASDAQ: VRXA) is developing antibody-based cancer therapies designed to improve treatment selectivity and potentially reduce toxicity to healthy tissues. At the center of its strategy is the proprietary BiTAC (Bi-targeted Tumor-Associated Cytotoxicity) platform, which uses two complementary molecules designed to activate cancer-killing activity only when both recognize targets on the same tumor cell. The company is applying this approach to antibody-drug conjugates (“ADCs”)…

Tuesday Oct 20, 2026 - 3:07 pm

InvestorNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Scales GelrinC Manufacturing Amidst Development Progress

Regentis Biomaterials (NYSE American: RGNT) is advancing its GelrinC hydrogel technology, designed to promote the regeneration of durable, natural-like cartilage in patients with painful knee cartilage injuries. The cell-free, off-the-shelf implant temporarily fills cartilage defects before gradually resorbing as surrounding tissue regenerates. Long-term MRI findings and peer-reviewed Phase II clinical data have provided evidence of cartilage maturation and durable structural repair, while the company has reported…

Friday Oct 16, 2026 - 3:35 pm

InvestorNewsBreaks – Nano-X Imaging Ltd. (NASDAQ: NNOX) Highlights Insider Buying Alongside Its Integrated Healthcare Technology Strategy

Recent SEC Form 4 filings disclosed open-market purchases of Nano-X Imaging Ltd.’s (NASDAQ: NNOX) (“Nanox”) ordinary shares by CEO Erez Meltzer and Board Director Dan Suesskind, adding to purchases reported in recent months by Meltzer, Suesskind and Board Director Nogah Keinan. The transactions reflect share purchases made directly in the open market by the company’s senior leadership and board members, with additional details available in…

Thursday Oct 15, 2026 - 3:43 pm

InvestorNewsBreaks – Earth Science Tech Inc. (ETST) Advances Expansion Plans with Meduvo and Zoolzy Acquisitions, Uplisting

Earth Science Tech (OTCQB: ETST), a healthcare, pharmacy, and telemedicine holding company, uplisted to the OTCQB Venture Market on Sept. 17, 2026, marking a key milestone in its fiscal 2027 growth strategy. The move follows a strong first quarter, with revenue increasing 3% to $9.0 million and net income rising 57% to $715,697, alongside acquisitions of Meduvo LLC, a compounding pharmacy, and Zoolzy LLC, a…

Wednesday Oct 14, 2026 - 3:12 pm

InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Gains FDA Clearance to Test Distinct Approach to MS Treatment

Quantum BioPharma (NASDAQ: QNTM), a biopharmaceutical company focused on advancing innovative therapies and technologies, received U.S. Food and Drug Administration (“FDA”) approval of its Investigational New Drug (“IND”) application for Lucid-MS, clearing the way for Phase 2 clinical testing of its multiple sclerosis (“MS”) candidate. The planned randomized, double-blind, placebo-controlled study will evaluate the drug’s efficacy, safety and tolerability in patients with MS, with researchers…

Wednesday Oct 14, 2026 - 2:31 pm

InvestorNewsBreaks – Nano-X Imaging Ltd. (NASDAQ: NNOX) Strengthens UK Market Access and Hospital-Based AI Capabilities

Nano-X Imaging Ltd. (NASDAQ: NNOX) (“Nanox”), an innovative technology company, is advancing Nanox.AI’s commercial and technology strategy through two developments aimed at expanding the use of AI in medical imaging. An exclusive three-year reseller agreement with Vertec Scientific, including minimum annual license commitments, establishes a dedicated UK channel for HealthOST, an AI-powered software solution that delivers qualitative and quantitative analysis of spinal CT images to…

Friday Oct 09, 2026 - 12:42 pm

InvestorNewsBreaks – Earth Science Tech Inc. (ETST) Builds Scalable Business Through Vertical Integration, Dual-Market Strategy

Earth Science Tech (OTC: ETST) is building a scalable, self-sustaining healthcare business through strategic acquisitions, end-to-end vertical integration, and a dual B2B and B2C revenue model. Its portfolio of pharmacies, telehealth platforms, and pharmaceutical distribution businesses connects patient consultations, clinical support, compounded medication production, and fulfillment while helping streamline operations and control supply costs. With its compounding pharmacies licensed across 34 U.S. jurisdictions, the company is…

Thursday Oct 08, 2026 - 2:21 pm

InvestorNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Seeks to Redefine Knee Cartilage Repair with Resorbable Hydrogel Technology

Regentis Biomaterials (NYSE American: RGNT) is developing GelrinC, an acellular hydrogel implant designed to shift knee cartilage treatment from symptom management toward early structural repair. Unlike microfracture, which can produce less-durable fibrocartilage, GelrinC is engineered to gradually resorb as surrounding cells regenerate hyaline-like cartilage, while avoiding cell harvesting and a second surgery. In a Phase II study, the company reported roughly 100% greater KOOS improvement versus…

Wednesday Sep 30, 2026 - 3:56 pm

InvestorNewsBreaks – Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) (FSE: W1H) Preps ONC010 for Clinical Translation

Disseminated on behalf of Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) (FSE: W1H) and may include paid advertising. Onco-Innovations (CBOE CA: ONCO)(OTCQB: ONNVF)(FSE: W1H) is advancing its preclinical oncology candidate ONC010, a nanoparticle-encapsulated PNKP inhibitor designed to disrupt DNA-repair mechanisms involved in cancer survival and treatment resistance, while building the manufacturing, regulatory and financial infrastructure needed for clinical development. The company reports completing a 300-gram API scale-up with approximately 99.3% purity, expanding…

Tuesday Sep 29, 2026 - 2:38 pm

InvestorNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Moves VXA-222 Bispecific ADC to Next Development Stage

VERAXA Biotech (NASDAQ: VRXA) has advanced its VXA-222 bispecific antibody-drug conjugate (“ADC”) program beyond the initial discovery phase following the completion of its collaboration with OmniAb, with the company now planning to engineer the final candidate using its antibody-engineering, linker and conjugation technologies and conduct in vitro and in vivo preclinical studies. VXA-222 employs an “AND-gate” design intended to recognize two tumor-associated antigens simultaneously, potentially…

Tuesday Sep 29, 2026 - 2:00 pm

InvestorNewsBreaks – Earth Science Tech Inc. (ETST) Adds California Hub to Growing Pharmacy Network

Earth Science Tech (OTC: ETST) recently continued its expansion in the healthcare, pharmacy and telemedicine sectors with the acquisition of Meduvo LLC, a California-based compounding pharmacy operating from a 2,000-square-foot facility in La Verne. The acquisition expands ETST’s pharmacy network to 34 U.S. jurisdictions and gives the company a West Coast operational hub, complementing its existing compounding pharmacy subsidiaries, RxCompoundStore.com and Mister Meds. The company…

Friday Sep 18, 2026 - 3:39 pm

InvestorNewsBreaks – Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) (FSE: W1H) Aligns Manufacturing, Preclinical Work and Clinical Planning for ONC010

Disseminated on behalf of Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) (FSE: W1H) and may include paid advertising. Onco-Innovations (CBOE CA: ONCO)(OTCQB: ONNVF)(FSE: W1H) is advancing its lead preclinical cancer candidate, ONC010, toward potential first-in-human testing by bringing together drug manufacturing, nanoparticle formulation, analytical development, preclinical studies and regulatory planning. ONC010 combines the company’s PNKP-targeting small molecule A83B4C63 with a micellar nanoparticle delivery system intended to enhance drug exposure and tumor accumulation,…

Friday Sep 18, 2026 - 2:59 pm

InvestorNewsBreaks – Nano-X Imaging Ltd. (NASDAQ: NNOX) Is Building End-to-End Platform for the Future of Medical Imaging

Nanox (NASDAQ: NNOX) is positioning itself as an integrated medical imaging and healthcare technology company, combining proprietary digital X-ray hardware, FDA-cleared AI applications, cloud software, teleradiology, and healthcare IT into an end-to-end platform designed to support earlier disease detection and more efficient care. Its ecosystem includes Nanox.ARC and the next-generation Nanox.ARC X imaging systems, Nanox.AI algorithms for identifying potential signs of chronic disease, Nanox.CLOUD for…

Thursday Sep 17, 2026 - 2:27 pm

InvestorNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Moves GelrinC Into Pivotal Stage of Development

Regentis Biomaterials (NYSE American: RGNT) was featured in a recent article that discussed its efforts to advance GelrinC, an off-the-shelf hydrogel implant designed to support the body’s natural regeneration of damaged knee cartilage. Delivered as a liquid and cured in place with UV light, GelrinC forms a temporary scaffold that gradually degrades over roughly six to nine months, creating an environment intended to support the development…

Wednesday Sep 16, 2026 - 3:37 pm

InvestorNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Developing Next-Gen Cancer Therapies with Dual-Targeting Approach

VERAXA Biotech (NASDAQ: VRXA) is developing an oncology pipeline centered on engineered antibody therapies, with a particular focus on bispecific antibody-drug conjugates (“ADCs”) and T-cell engagers (“TCEs”). Its proprietary BiTAC platform uses a dual-targeting “AND-gated” approach intended to activate therapeutic effects preferentially when two tumor-associated targets are present on the same cancer cell, potentially addressing the challenge of on-target, off-tumor toxicity. The company has reported…

Wednesday Sep 16, 2026 - 3:07 pm

InvestorNewsBreaks – Earth Science Tech Inc. (ETST) Targets Greater Scale Following Q1 Growth

Earth Science Tech (OTC: ETST) recently reported Q1 2027 results that management says demonstrate continued progress from its strategy of acquiring and scaling profitable healthcare, pharmaceutical, and telemedicine businesses. For the quarter ended June 30, 2026, revenue rose 3% to $9.0 million, gross profit increased 3.1% to $6.3 million, net income climbed 57% to $715,697, operating cash flow more than doubled to $707,131, and total…

Monday Sep 14, 2026 - 9:35 am

InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Featured in NetworkNewsAudio APR Highlighting FDA Clearance of Lucid-MS IND

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) was featured in a NetworkNewsAudio Audio Press Release titled “A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach,” highlighting FDA clearance of the company’s Investigational New Drug (“IND”) application for Lucid-MS. According to the company, the approximately 15,000-page IND submission included a comprehensive package…

Thursday Sep 10, 2026 - 12:57 pm

InvestorNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Bolsters Scientific Leadership Ahead of BiTAC(R) Clinical Development

VERAXA Biotech (NASDAQ: VRXA) recently appointed antibody therapeutics specialist Dr. Christoph Erkel as its chief scientific officer, taking responsibility for advancing the company’s proprietary BiTAC(R) technology and broader oncology pipeline toward clinical development. The company’s lead BiTAC-TCE program uses a conditionally active, dual-targeting approach designed to selectively activate T cells against cancer cells while potentially limiting effects on healthy tissue. Recent scientific advice from Germany’s…

Thursday Sep 10, 2026 - 12:12 pm

InvestorNewsBreaks – Earth Science Tech Inc.’s (ETST) B2B-B2C Healthcare Platform Powers Continued Revenue Growth

Earth Science Tech (OTC: ETST) is positioning itself as a vertically integrated healthcare company through its subsidiaries RxCompoundStore, Mister Meds, and Peaks Curative, combining compounding pharmacy, telemedicine, clinical support, and fulfillment capabilities. Its B2B and B2C business model allows the company to serve independent clinics while also selling customized medications directly to consumers, creating diversified revenue streams across physical and digital healthcare operations. In FY2026,…

Wednesday Sep 02, 2026 - 3:33 pm

InvestorNewsBreaks – Regentis Biomaterials Ltd.’s (NYSE American: RGNT) GelrinC Advances Toward New Era of Regenerative Orthopedic Care

Regentis Biomaterials (NYSE American: RGNT) is advancing a regenerative approach to cartilage repair with GelrinC, a cell-free, off-the-shelf hydrogel implant designed to create a temporary environment that supports the body’s natural ability to regenerate damaged knee cartilage. Unlike conventional implants that primarily replace or reinforce damaged tissue, GelrinC is injected into a cartilage lesion and cured in place with ultraviolet light before gradually degrading as new…

Thursday Aug 27, 2026 - 3:29 pm

InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Moves Myelin-Protecting MS Therapy to Phase 2 Development

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is a biopharmaceutical company focused on advancing innovative therapies and technologies. The company was featured in a recent article that discussed its efforts to advance Lucid-MS, an oral investigational therapy designed to inhibit demyelination and protect myelin in people with multiple sclerosis, as MS drug…

Thursday Aug 27, 2026 - 3:02 pm

InvestorNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Expands GelrinC Clinical and Commercial Pathways

Regentis Biomaterials (NYSE American: RGNT) is advancing its GelrinC cell-free cartilage repair implant along parallel U.S. clinical and European commercial tracks, with more than half of the 80-patient pivotal Phase III SAGE study enrolled and recruitment targeted for completion in the third quarter of 2026. The FDA-approved single-arm study uses a historical microfracture control dataset owned by Regentis, and the company reports that the first 40…

Thursday Aug 27, 2026 - 2:23 pm

InvestorNewsBreaks – Earth Science Tech Inc. (ETST) Marks Growth as Avenvi Expands Asset Base

Earth Science Tech (OTC: ETST) was featured in a recent article that discussed its strengthened position among OTC-listed companies through consistent financial growth, timely reporting, vertical integration, prudent capital allocation, and ownership of hard real estate assets. Revenue increased to $35.7 million in FY2026 from $33.1 million in FY2025 and $11.95 million in FY2024, while gross profit rose to $25.5 million from $24.3 million and…

Wednesday Aug 19, 2026 - 12:53 pm

InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Explores Myelin Protection as New Focus in MS Treatment

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is developing Lucid-MS around the idea that multiple sclerosis disability can progress independently of relapses, known as progression independent of relapse activity (“PIRA”). A recent article discusses chronic active, or “smoldering,” lesions and compartmentalized inflammation within the central nervous system as potential contributors to ongoing…

Tuesday Aug 18, 2026 - 1:43 pm

InvestorNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Marks Key IP Milestone for GelrinC Manufacturing

Regentis Biomaterials (NYSE American: RGNT) is strengthening the manufacturing and intellectual property foundation behind its GelrinC cartilage-repair technology as it moves toward broader commercialization. The company recently received a Japanese Notice of Allowance for patent protection covering the organic solvent-free manufacturing process and ready-to-use liquid formulation behind GelrinC. This followed a recent U.S. issuance that expanded its global IP portfolio to nearly 30 patents. Regentis’ proprietary…

Tuesday Aug 18, 2026 - 12:46 pm

InvestorNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Turns to AI to Advance Precision Oncology

VERAXA Biotech (NASDAQ: VRXA) was featured in a recent article highlighting how its collaboration with AI-focused research organization Ardigen could strengthen the company’s oncology pipeline as artificial intelligence plays an increasingly important role in drug discovery. By combining Ardigen’s expertise in AI, computational biology and bioinformatics with VERAXA’s proprietary BiTAC(R) platform, the companies aim to use AI to identify optimal dual-target combinations for T-cell engagers…

Friday Aug 14, 2026 - 2:43 pm

InvestorNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) Builds Foundation for Biomarker-Driven Cancer Therapy

Disseminated on behalf of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) is advancing its precision oncology strategy through ONC010, a nanoparticle-encapsulated PNKP inhibitor being developed for biomarker-selected cancers. The company is building the manufacturing and scientific foundation needed to advance the program toward first-in-human studies, including polymer process development and analytical characterization activities with Nanosoft Polymers and…

Friday Aug 14, 2026 - 1:16 pm

InvestorNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Builds Commercial Case for GelrinC in Multi-Billion Knee Cartilage Repair Market

Regentis Biomaterials (NYSE American: RGNT) was featured in a recent article highlighting the potential of its GelrinC cell-free hydrogel implant to address longstanding challenges in focal knee injuries through an off-the-shelf treatment designed to simplify surgical workflows, support faster recovery and promote durable tissue regeneration. The company recently received European regulatory approval for a next-generation, solvent-free manufacturing process that increases production yield by approximately 400%, supporting…

Friday Aug 07, 2026 - 2:50 pm

InvestorNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Moves GelrinC Closer to Regulatory and Commercial Milestones

Regentis Biomaterials (NYSE American: RGNT) is advancing its GelrinC hydrogel-based cartilage regeneration technology toward key clinical, regulatory and commercial milestones amid growing interest in regenerative orthopedic solutions. GelrinC is an off-the-shelf, cell-free implant designed for a streamlined, single-step procedure that supports cartilage regeneration without the cell harvesting and laboratory processing required by some alternative approaches. Regentis is continuing enrollment in its U.S. clinical study, preparing for…

Friday Aug 07, 2026 - 2:08 pm

InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Two-Pronged Approach to Neurological Health

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on advancing innovative therapies and technologies, is developing a two-pronged strategy addressing neurological health through its investigational multiple sclerosis therapy Lucid-MS and its proprietary dietary supplement unbuzzd. Lucid-MS is designed to target PAD2, an enzyme associated with myelin degradation, with the goal…

Friday Aug 07, 2026 - 12:54 pm

InvestorNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Builds Strategic Position in Antibody Therapeutics Market

VERAXA Biotech (NASDAQ: VRXA) is developing next-generation antibody therapeutics across antibody-drug conjugates (“ADCs”) and T-cell engagers (“TCEs”), two areas that continue to attract significant pharmaceutical investment. A recent article highlights major transactions to illustrate how differentiated antibody-engineering platforms can attract substantial financial commitments even before clinical development reaches advanced stages. VERAXA’s proprietary BiTAC platform supports a pipeline that includes bispecific ADCs, T-cell engagers and engineered…

Wednesday Aug 05, 2026 - 1:10 pm

InvestorNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) Combines Targeted Cancer Therapy, Nanotechnology and AI

Disseminated on behalf of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) is pursuing an integrated approach to cancer drug development that combines three emerging areas: PNKP-targeted DNA damage response (“DDR”) inhibition, nanoparticle drug delivery and artificial intelligence. Its lead candidate, ONC010, pairs a PNKP inhibitor with a polymer micelle carrier intended to improve drug solubility, tumor accumulation…

Wednesday Aug 05, 2026 - 12:46 pm

InvestorNewsBreaks – Earth Science Tech Inc. (ETST) Advances Telehealth Position Through Technology, Vertical Integration

Earth Science Tech (OTC: ETST) was featured in a recent article that discussed its positioning in the growing telehealth and healthcare markets through strategic investments, vertical integration and proprietary technology. Through subsidiaries such as DOConsultations LLC and Las Villas Health Care Inc., the company provides online and brick-and-mortar telehealth services focused on wellness and direct-to-patient delivery, while also targeting the expanding peptide therapy market. ETST’s…

Friday Jul 31, 2026 - 3:47 pm

InvestorNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Advances Regenerative Solution for Major Unmet Need in Cartilage Repair

Regentis Biomaterials (NYSE American: RGNT) was featured in a recent article that discussed its efforts to advance GelrinC, a potentially first-in-class, off-the-shelf cartilage regeneration platform, and the company’s broader mission to establish a new standard of care in cartilage repair. “Regentis is developing regenerative biomaterial technology as healthcare shifts toward therapies designed to restore damaged tissue rather than simply manage symptoms. With cartilage defects affecting hundreds…

Friday Jul 31, 2026 - 3:32 pm

InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances MS Imaging Study with Encouraging Preliminary Results

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) has reached the halfway point in patient enrollment for its pilot MS imaging study with Massachusetts General Hospital, with preliminary PET imaging data showing encouraging signals in acute MS lesions. The novel imaging technique is designed to distinguish demyelinated nerve fibers that may still be…

Thursday Jul 30, 2026 - 12:15 pm

InvestorNewsBreaks – Earth Science Tech Inc.’s (ETST) Vertical Integration Drives Revenue Growth, Product Expansion

Earth Science Tech (OTC: ETST) is leveraging a diversified, vertically integrated business model spanning pharmaceuticals, telemedicine, retail and real estate. Through subsidiaries including Peak Curative, RxCompound and Mister Meds, the company connects telemedicine consultations, compounding pharmacies and medication fulfillment within an end-to-end healthcare ecosystem. Its MOCTeledoc platform also provides B2B technology and clinical staffing solutions, allowing ETST to generate revenue by supporting other digital health…

Wednesday Jul 29, 2026 - 3:48 pm

InvestorNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Targets $3 Billion Cartilage Repair Market with Cell-Free Gelrin C

Regentis Biomaterials (NYSE American: RGNT) is positioning its Gelrin C hydrogel as a practical regenerative medicine solution for cartilage damage that could help address the substantial clinical and economic burden associated with knee osteoarthritis (“OA”). Gelrin C is a cell-free, off-the-shelf hydrogel administered in a single 10-minute procedure, designed to support cartilage regeneration while avoiding the multiple surgeries, specialized laboratory processing and higher costs associated with…

Wednesday Jul 29, 2026 - 3:08 pm

InvestorNewsBreaks – MindBio Therapeutics Corp.’s (CSE: MBIO) (OTCQB: MBQIF) Edge AI Kiosks Target Rapid, Scalable Impairment Screening

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. MindBio Therapeutics (CSE: MBIO) (OTCQB: MBQIF) has completed and delivered its first Edge AI Intoxication and Fatigue Detection Kiosk prototypes, advancing its efforts to commercialize voice-based impairment detection technology for workplace safety applications. The kiosks use artificial intelligence to analyze short voice samples for more than 140 acoustic markers…

Monday Jul 27, 2026 - 3:19 pm

InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Executive Outlines Lucid-MS Development Strategy and Commercial Growth Plans

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on advancing innovative therapies and technologies, was featured in a recent episode of the BioMedWire Podcast. During the program, Executive Co-Chairman and Co-Founder Anthony Durkacz discussed the company’s strategy for advancing Lucid-MS, its lead drug candidate for multiple sclerosis, as well…

Monday Jul 27, 2026 - 2:42 pm

InvestorNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) Moves Lead Oncology Candidate Toward Future Clinical Studies

Disseminated on behalf of Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) is advancing the development of its lead oncology candidate, ONC010, a PNKP inhibitor designed to disrupt cancer cells’ DNA repair mechanisms and potentially address treatment resistance. The company recently advanced kilogram-scale manufacturing of a key precursor used to produce ONC010’s active pharmaceutical ingredient, supporting future formulation…

InvestorNewsBreaks

NewsBreak Category: Biotechnology

Get Started with InvestorWire

Press Distribution

Explore Press Distribution Solutions

Discover Add-on Solutions